Relationship Between Postoperative Neutrophil–Lymphocyte Ratio and 6-Month Primary Patency of Percutaneous Transluminal Angioplasty in Femoropopliteal disease With Drug-Coated and Uncoated Balloons

Zhen, Yanhua; Chang, Zhihui; Liu, Zhaoyu; Zheng, Jiahe

doi:10.1177/0003319718799589

Cited by 8 publications

(12 citation statements)

References 33 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li et al [30] concluded that higher pre-NLR and pre-PLR levels were independent risk factors for the development of in-stent restenosis in patients who underwent drug-eluting stent implantation for coronary chronic total occlusion lesions. However, in the study, pre-NLR was not an independent predictor of PP at 6 months, which is in accordance with our previous report [16]. Larger samples are still needed to confirm our conclusion in the future.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease

Zhen

Chang

Liu

et al. 2020

BMC Cardiovasc Disord

Self Cite

View full text Add to dashboard Cite

Background: Inflammatory reaction is an essential factor in the occurrence, development and prognosis of femoropopliteal disease (FPD). The ratio of platelets to lymphocytes (PLR) is a new indicator reflecting platelet aggregation and burden of systemic inflammation. Our study is to explore the association between preoperative platelet-to-lymphocyte ratio (pre-PLR) and 6-month primary patency (PP) after drug-coated balloon (DCB) in FPD. Methods: There were 70 patients who underwent DCB for FPD contained in the study. According to 6-month PP, patients were divided into group A (PP ≥6 months, n = 54) and group B (PP < 6 months, n = 16). Logistic regression analysis was used to identify potential predictors for 6-month PP after DCB in FPD. A receiver operating characteristic (ROC) curve analysis was used to identify the cutoff value of pre-PLR to predict 6-month PP. Results: Logistic regression analysis showed that pre-PLR (OR: 1.008, 95% CI: 1.001-1.016, P = 0.031) and lesion length > 10 cm (OR: 4.305, 95% CI: 1.061-17.465, P = 0.041) were independently predictive for 6-month PP. The cutoff value of pre-PLR obtained from the ROC analysis was 127.35 to determine 6-month PP with the area of 0.839. Subgroup analysis was conducted based on the cutoff value of pre-PLR. The 6-month PP in the group of pre-PLR < 127.35 was higher than that of pre-PLR ≥ 127.35 group (p < 0.001). Conclusions: The present study indicated that an elevated pre-PLR was an effective additional indicator for predicting early PP in FPD after DCB.

show abstract

Section: Discussionsupporting

confidence: 91%

“…Pre-dilatation with uncoated balloon was conducted conventionally before DCB. The DCB used in this study was coated with paclitaxel at 3 μg/mm 2 , and the method of use was as described previously [16].…”

Section: Methodsmentioning

confidence: 99%

Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease

Zhen

Chang

Liu

et al. 2020

BMC Cardiovasc Disord

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interestingly, NLR after femoropopliteal PTA without stent implantation was shown to be significantly lower in patients treated with a drug-coated balloon (DCB) compared to patients treated with PTA with a uncoated balloon. Moreover, it was associated with a significantly higher primary patency rate after six months [78].…”

Section: Inflammatory Cellsmentioning

confidence: 92%

Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes

Jakubiak

Pawlas

Cieślar

et al. 2021

IJERPH

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a strong risk factor for the development of cardiovascular diseases such as coronary heart disease, cerebrovascular disease, and peripheral arterial disease (PAD). In the population of people living with DM, PAD is characterised by multi-level atherosclerotic lesions as well as greater involvement of the arteries below the knee. DM is also a factor that significantly increases the risk of lower limb amputation. Percutaneous balloon angioplasty with or without stent implantation is an important method of the treatment for atherosclerotic cardiovascular diseases, but restenosis is a factor limiting its long-term effectiveness. The pathogenesis of atherosclerosis in the course of DM differs slightly from that in the general population. In the population of people living with DM, more attention is drawn to such factors as inflammation, endothelial dysfunction, platelet dysfunction, blood rheological properties, hypercoagulability, and additional factors stimulating vascular smooth muscle cell proliferation. DM is a risk factor for restenosis. The purpose of this paper is to provide a review of the literature and to present the most important information on the current state of knowledge on mechanisms and the clinical significance of restenosis and in-stent restenosis in patients with DM, especially in association with the endovascular treatment of PAD. The role of such processes as inflammation, neointimal hyperplasia and neoatherosclerosis, allergy, resistance to antimitotic drugs used for coating stents and balloons, genetic factors, and technical and mechanical factors are discussed. The information on restenosis collected in this publication may be helpful in planning further research in this field, which may contribute to the formulation of more and more precise recommendations for the clinical practice.

show abstract

“…Similarly, target lesion patency or restenosis after DCB has also received increasing attention from clinicians. In a retrospective study ( 18 ), Zhen et al found that the 6-month target lesion patency rate (6-month primary patency) after DCB treatment for femoropopliteal artery disease was 77.3%, while the 6-month target lesion patency after uncoated balloon (UCB) treatment was only 53.2% ( P = 0.011). The definition of patency in the previous study is <50% lumen stenosis and the ratio of peak systolic velocity >2.4, which is consistent with the definition of restenosis in this study ( 18 ).…”

Section: Discussionmentioning

confidence: 99%

“…In a study with long-term follow-up, the results showed that femoropopliteal artery lesions with different TASC II classifications had different patency rates at 5-year postoperative follow-up after endovascular therapy, with type D lesions generally having the lowest rate of only 34% ( 17 ). A certain percentage of patients developed target lesion restenosis after DCB treatment of the femoropopliteal artery ( 18 , 19 ), and studies even found that DCB treatment of femoropopliteal artery disease increases the risk of death in patients ( 20 ). Therefore, screening the predictive factors of restenosis after DCB treatment for femoropopliteal artery disease has important clinical significance.…”

Section: Introductionmentioning

confidence: 99%

Neutrophil-to-Lymphocyte Ratio Predicts Restenosis After Drug-Coated Balloon Therapy for Femoropopliteal Artery Lesions: A Retrospective Study

Wang¹,

Lei²,

Gu³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundPeripheral artery disease (PAD) is a common atherosclerotic vascular disease. The use of drug-coated balloon (DCB) for the treatment of femoropopliteal artery disease has gradually increased. A certain percentage of patients developed target lesion restenosis after DCB treatment of the femoral popliteal artery. The neutrophil-to-lymphocyte ratio (NLR) is closely related to the level of inflammatory activity and has predictive value for atherosclerotic vascular disease. This study aimed to analyze the relationship between NLR and 1-year restenosis after DCB for femoropopliteal artery disease.MethodsPatients with femoropopliteal artery disease who were treated with DCBs at our hospital from May 2016 to December 2020 were retrospectively included. Baseline data during the patient’s first hospital stay and data during follow-up were collected. Demographic data, laboratory test results, lesion examination results, and major adverse events during the follow-up period were collected. Logistic regression was used to analyze the factors associated with restenosis after DCB.ResultsA total of 117 patients were included. During 1-year follow-up, 19 cases (16.2%) of restenosis were detected. Five of these patients (4.3% of total included patients) were readmitted for symptomatic ischemia. No deaths or amputations occurred. Baseline NLR in patients with restenosis was higher than that in patients without restenosis (2.4 (2.1, 3.4) vs. 1.8 (1.3, 2.3), P < 0.001). Logistic univariate and multivariate analysis showed that baseline hs-CRP level (OR = 1.10, 95%CI: 1.05–1.34), lesion length (OR = 1.04, 95%CI: 1.02–1.27), use of rivaroxaban (OR = 1.08, 95%CI: 1.05–1.39), NLR (OR = 1.47, 95%CI: 1.13–2.48), LDL-C level (OR = 1.25, 95%CI: 1.05–1.52), and diabetes (OR = 1.25, 95%CI: 1.05–1.52) = 1.18, 95%CI: 1.06–1.66) were predictors of restenosis.ConclusionBaseline NLR before DCB can predict the risk of restenosis after surgery.

show abstract

Relationship Between Postoperative Neutrophil–Lymphocyte Ratio and 6-Month Primary Patency of Percutaneous Transluminal Angioplasty in Femoropopliteal disease With Drug-Coated and Uncoated Balloons

Cited by 8 publications

References 33 publications

Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease

Platelet to lymphocyte ratio predicting 6-month primary patency of drug-coated balloon for femoropopliteal disease

Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes

Neutrophil-to-Lymphocyte Ratio Predicts Restenosis After Drug-Coated Balloon Therapy for Femoropopliteal Artery Lesions: A Retrospective Study

Contact Info

Product

Resources

About